San Francisco, 24 October 2018 , The global therapeutic drug monitoring market is expected to reach over USD 3.37
billion by 2024, according to a new report by Grand View Research, Inc. Recent
technological advancements in the Point-of-Care (PoC) devices hold considerable
transformative promises for the personalized predictive and preventive
medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the
devising of personalized treatment plans for patients; and the advent of PoC
diagnostic devices that yield quantitative measurements of the drug
concentration plays a pivotal role in supporting the development of the
precision medicine field in the healthcare sector. However, the broad
application of the PoC devices for patient monitoring is still lagging behind.
The presence of this untapped opportunity is one of the high impact rendering
drivers for the market growth.
The employment of continuous therapeutic
drug and metabolite monitoring in the early phase of the medication regimen,
administered post-organ transplantation, forms a major application in the areas
of critical care medicine and organ transplantation, which is expected to
propel the growth of the therapeutic drug monitoring market over the forecast
period. In addition, the imposing burden of diseases, such as epilepsy and
cancer, the rising government initiatives, and the presence of high-unmet needs
are some of the crucial determinants expected to further favor the emergence of
this market.
Full Research Report On Therapeutic Drug Monitoring
Market Analysis:
www.grandviewresearch.com/industry-analysis/therapeutic-drug-monitoring-market
www.grandviewresearch.com/industry-analysis/therapeutic-drug-monitoring-market
Further key findings from the study suggest:
·
The consumables segment covered over 65% of
the market share in 2015 as a consequence of the extensive requirement of the
consumables in the research laboratories and due to the repeat purchase of the
kits and reagents.
·
The immunoassay segment held the largest
market share in 2015. The presence of several commercially available
immunoassays combined with their associated benefits including the cost
effectiveness and easy-to-handle nature of the products are the key drivers for
the growth of this segment.
·
The proteomics category is expected to be
the fastest growing technology segment due to the advent of various proteomic
technologies, such as isotope-coded affinity tags, next generation sequencing,
and protein microarray platforms that enable rapid mining of the proteome.
·
The hospital is the largest end-use segment
with a share of over 60% in 2015. In larger hospitals, various underlying
technologies are employed to perform immunoassays; these comprise
chemiluminescence, nephelometry, colorimetry, and fluorescence, which are
available for the testing of a wide ranging drug panel.
·
The drug monitoring for the
immunosuppressants is one of the fastest growing application segments owing to
the introduction of novel TDM point-of-care testing devices for the evaluation
of the concentration of administered immunosuppressants and the complementary
metabolites, in order to achieve a prominent therapeutic effect while
preventing drug toxicity events in patients that have undergone transplantations.
·
In 2015, North America was the highest
revenue generating region with revenue generated over USD 900 million. The
rising number of R&D activities coupled with the high awareness about
personalized therapy is the major determining factor for the large share
captured by the North America region.
·
Few of the leading market players are Roche
Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad
Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent
Technologies, Inc., bioMérieux, Inc., and Alere, Inc. The persistent R&D
efforts are being undertaken along with numerous other strategic endeavors
being adopted by the market players with the objective of enhancing the present
drug monitoring practices and to develop novel technologies.
Browse
More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the therapeutic drug
monitoring market on the basis of product, technology, application,
end-use, and region:
Therapeutic Drug Monitoring Market, Product
Outlook, by Revenue (USD Million, 2013 - 2024)
·
Consumables
·
Equipment
·
Others
Therapeutic Drug Monitoring Market,
Technology Outlook, by Revenue (USD Million, 2013 - 2024)
·
Immunoassays
·
Proteomic technologies
·
Others
Therapeutic Drug Monitoring Market Drug,
Class Outlook, by Revenue (USD Million, 2013 - 2024)
·
Anti-epileptics
·
Antibiotics
·
Immunosuppressants
·
Psychoactive drugs
·
Antiarrhythmic drugs
·
Others
Therapeutic Drug Monitoring Market, End-use
Outlook, by Revenue (USD Million, 2013 - 2024)
·
Hospital labs
·
Private labs
·
Others
Therapeutic Drug Monitoring Market,
Regional Outlook, by Revenue (USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
MEA
o
South Africa
Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-medical-alert-personal-emergency-response-system-pers-market
www.grandviewresearch.com/press-release/global-medical-alert-personal-emergency-response-system-pers-market
About Grand View
Research
Grand View Research, Inc.
is a U.S. based market research and consulting company, registered in the State
of California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/
No comments:
Post a Comment